Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in ...

As spine leaders look ahead to 2026, enthusiasm around regenerative medicine and neuromodulation continues to build. But much of the conversation still flattens a field that is far more complex than ...

As people with α-gal syndrome seek to boost awareness, researchers are looking to harness the molecule for new therapies ...

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical ...

Report analyzes publicly available category information, company-stated product details, and consumer search patterns as ...

“This work is unique in its scale of assessment of food additives in a large number of study participants, and also puts added focus on the recognition by the International Agency for Research on ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...

Portable chargers are supposed to be the quiet workhorses in your bag, not a source of fire risk on your desk or nightstand.

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...

A study led by Maria Carmo-Fonseca at GIMM has helped clarify one of the main limitations of lab-grown heart cells, which are ...

Mitochondrial dysfunction is associated with various chronic diseases and cancers, including neurodegenerative diseases and ...